Jazz Pharmaceuticals plc cash flow to debt ratio of 25.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Jazz Pharmaceuticals plc's free cash flow has decreased 14.97% from $1.35B last year to $1.15B, signaling decreasing performance

Jazz Pharmaceuticals plc's debt to equity ratio is 0.92, which means that the company's assets are unhealthy financed, signaling financial risk.

Jazz Pharmaceuticals plc's debt has decreased relative to shareholder equity from 1.51 last year to 0.92 today, signaling strengthened financials

Jazz Pharmaceuticals plc has a net debt to EBITDA ratio of 27.49x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Jazz Pharmaceuticals plc's interest coverage ratio of 7.35 indicates that earnings with good margin can cover interest payments on company debt

Jazz Pharmaceuticals plc's profit margin has increased (48.53%) in the last year from 13.77% to 20.45%, signaling increasing performance

Jazz Pharmaceuticals plc's short-term assets of $4.17B exceed its short-term liabilities of $2.24B

Jazz Pharmaceuticals plc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Jazz Pharmaceuticals plc's return on equity of 21.37%, is higher than 15.00%, indicating good performance

Jazz Pharmaceuticals plc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Jazz Pharmaceuticals plc had positive net income in only 2 out of 5 years, indicating unstable earnings

Jazz Pharmaceuticals plc has positive free cash flow, indicating the company generates cash after capital expenditures

Jazz Pharmaceuticals plc has a free cash flow yield of 7.11%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Jazz Pharmaceuticals plc's yearly earnings has decreased 163.58% since last year from $560.12M to $-356.15M, signaling decreasing performance

Jazz Pharmaceuticals plc's yearly revenue has increased 4.88% since last year from $4.07B to $4.27B, signaling increasing performance

ROIC 14.46% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Jazz Pharmaceuticals plc's 3-year revenue CAGR of 5.26% is positive, indicating growing revenue over the past 3 years

Jazz Pharmaceuticals plc had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Jazz Pharmaceuticals plc had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Jazz Pharmaceuticals plc is undervalued relative to its fair value price of 308.49 based on Discounted Cash Flow model

Jazz Pharmaceuticals plc has an earnings yield of 5.80%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Jazz Pharmaceuticals plc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Jazz Pharmaceuticals plc has an EV/EBITDA ratio of 176.06x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Jazz Pharmaceuticals plc is overvalued relative to its fair value price of 110.14 based on Earnings Fair Value model

Jazz Pharmaceuticals plc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jazz Pharmaceuticals plc has a price-to-book ratio of 3.38x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Jazz Pharmaceuticals plc has a price-to-sales ratio of 3.52x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue